Treat Both the Candida Glabrata AND the Vaginal Atrophy Simultaneously
In a 69-year-old woman with fluconazole-resistant C. glabrata and vaginal atrophy, you must address BOTH conditions—the fungal infection requires specific antifungal therapy while vaginal estrogen will improve the underlying atrophic environment that predisposes to recurrent infections and urinary symptoms.
The Dual Problem
This patient has two distinct but interrelated conditions:
- Active C. glabrata infection (fluconazole-resistant)
- Vaginal atrophy (genitourinary syndrome of menopause/GSM)
The vaginal atrophy is likely contributing to her dysuria and creating an environment that promotes candidal colonization and infection. However, the presence of atrophy does NOT negate the need to treat the documented C. glabrata infection 1.
Treatment Algorithm
Step 1: Treat the C. glabrata Infection First
For fluconazole-resistant C. glabrata vulvovaginitis, use intravaginal boric acid 600 mg daily for 14 days 1. This is the first-line recommendation with strong evidence support.
Alternative options if boric acid fails or is unavailable:
- Nystatin intravaginal suppositories 100,000 units daily for 14 days 1
- Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream for 14 days (requires compounding) 1
Critical point: The guidelines emphasize determining whether C. glabrata represents true infection versus colonization 1. Given her symptomatic dysuria with positive culture, this represents true infection requiring treatment.
Step 2: Initiate Vaginal Estrogen Therapy Concurrently
Start low-dose vaginal estrogen immediately to address the underlying atrophic vaginitis 2, 3. The vaginal atrophy is contributing to her urinary symptoms and creating an environment conducive to recurrent infections 4, 5, 6.
Dosing options 3:
- Estradiol vaginal cream 0.01%: 2-4 g daily for 1-2 weeks, then taper to half dose for another 1-2 weeks, then maintenance of 1 g one to three times weekly
- Alternative formulations include vaginal tablets or rings based on patient preference 2
Why Both Treatments Are Essential
The Infection Won't Resolve Without Antifungal Therapy
C. glabrata is inherently less susceptible to azoles, and fluconazole failure confirms resistance 1. Vaginal estrogen alone will not eradicate an established C. glabrata infection, though it may reduce future susceptibility 7.
The Atrophy Won't Improve Without Estrogen
At age 69, this patient almost certainly has significant vaginal atrophy contributing to:
- Dysuria (a classic GSM symptom) 2, 5, 6
- Altered vaginal pH and epithelium that promotes candidal overgrowth 5, 8
- Increased susceptibility to recurrent infections 4, 6
Studies show that vaginal estrogen users have significantly lower incidence of urinary tract symptoms (11.8% vs 17.2%, p<0.001) 4, and GSM affects 50-70% of postmenopausal women 4.
Common Pitfalls to Avoid
Don't treat only the atrophy and ignore the documented infection: This leaves active C. glabrata untreated, which can lead to persistent symptoms and potential complications.
Don't delay estrogen therapy: Starting vaginal estrogen concurrently (not sequentially) addresses the underlying predisposing factor and improves long-term outcomes 9, 8.
Don't confuse candiduria with vulvovaginitis: The guidelines for urinary candidiasis differ significantly 1. Her presentation with dysuria and vaginal symptoms suggests vulvovaginitis, not isolated candiduria.
Don't use systemic fluconazole for C. glabrata: Azole therapy is "frequently unsuccessful" for C. glabrata vulvovaginitis 1, and she has already failed fluconazole.
Safety Considerations
Low-dose vaginal estrogen is safe even during active candidal infection 2. Studies show no increase in serum estradiol levels or endometrial hyperplasia risk with local low-dose preparations 2. The benefits of treating GSM far outweigh theoretical risks, particularly given the high prevalence of undertreatment in this population 4, 9.
Long-Term Management
After completing the 14-day antifungal course, continue vaginal estrogen indefinitely as maintenance therapy for GSM 2, 3. This prevents recurrence of both atrophic symptoms and reduces susceptibility to future infections 4, 6. The typical maintenance regimen is 1 g of vaginal estrogen cream 1-3 times weekly 3.